14 / 30
Abou-Alfa GK, et al.
N Engl J Med
2018;379:54–63
.
BASELINE CHARACTERISTICS
Cabozantinib (N=470)
Placebo
(N=237)
Median age, years (range)
64 (22‒86)
64 (24‒86)
Male, %
81
85
ECOG Performance Status 0 / 1, %
52 / 48
55 / 45
AFP ≥ 400 ng/mL, %
41
43
Enrollment Region, %
Asia / Europe / N.America / Australia _New Zealand
25 / 49 / 23 / 3
25 / 46 / 25 / 5
Aetiology of HCC, %
HBV
38
38
HCV
24
23
Alcohol use
24
16
Unknown
16
20
Extrahepatic spread of disease, %
79
77
Macrovascular invasion, %
27
34
Extrahepatic spread and/or macrovascular invasion, %
85
84
CELESTIAL Phase III study